Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops the SSi Mantra surgical robotic system and SSi Mudra surgical instruments. Company news frequently highlights progress toward its stated goal of making robotic surgery more affordable and accessible to a larger segment of the global population.
News updates for SSII often cover developments related to the SSi Mantra platform, including new installations, clinical milestones, and telesurgery achievements. The company has reported thousands of surgical procedures performed using the SSi Mantra, including cardiac procedures and telesurgeries across categories such as pediatric, urology, gynecology, oncology, and general surgery. Announcements have also described the introduction of smaller 5-millimeter instruments designed for pediatric, cardiac, and head and neck surgery, as well as the use of the SSi Mantra Tele Surgeon Console for remote procedures.
Investors and healthcare professionals following SS Innovations can expect news on quarterly and annual financial results, including revenue from system sales, instrument sales, warranty sales, and lease income. Regulatory and clinical updates are another recurring theme, such as the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for multiple specialty indications.
This news feed aggregates press releases, SEC-related announcements, and other public communications from SS Innovations. It provides a single location to review updates on product developments, clinical experience, regulatory milestones, and corporate events related to SSII and its surgical robotic technologies.
SS Innovations (Nasdaq: SSII) unveiled multiple surgical robotic concepts at SMRSC 2026 on April 23, 2026, in New Delhi, including the SSi Vimana Aero drone-delivered surgical system, SSi Avtara humanoid platform, SSi Operion mobile operating room, and single-arm endoscopy/ultrasound assist carts.
SMRSC 2026 drew over 1,600 onsite and 1,800 virtual attendees; the company demonstrated the SSi Mantra with 10 live telesurgeries and 13 live robotic surgeries. Single-arm carts are in early clinical validation in India.
SS Innovations (Nasdaq: SSII) will host the Global Multi-Specialty Robotic Surgery Conference, SMRSC 2026, in New Delhi, India from April 9-11, 2026. The event features live telesurgeries, the SSi MantrAsana tele surgeon console, the SSi Vimana Aero drone trauma system, Project Operion and the MantraM mobile unit.
The conference aims to showcase multispecialty robotic demos, training, telesurgery protocols and innovations that support decentralized access to robotic surgical care.
SS Innovations (Nasdaq: SSII) received regulatory approvals for the SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya.
The approvals were granted by INVIMA (Colombia, Nov 2025), DGPA&DC (Oman, Nov 2025), NMRA (Sri Lanka, Jan 2026) and PPB (Kenya, Jan 2026). The SSi Mantra now has approval in eleven countries and a cumulative installed base of 168 systems with 7,885 surgeries through Dec 31, 2025.
SS Innovations (Nasdaq: SSII) announced regulatory approval for telesurgeries using its SSi Mantra surgical robotic system in Indonesia and the Philippines on March 18, 2026. The company also reported surpassing 150 cumulative telesurgeries, with high‑volume sessions in India demonstrating multi‑case capability.
Recent operational highlights include 18 inter‑hospital telesurgeries on February 14, 2026, and a 24‑case telesurgery marathon on December 23, 2025, using the portable SSi MantraAsana console.
SS Innovations (Nasdaq: SSII) reported strong 2025 growth with revenue up 105.7% to $42.5M and gross margin expanding to 46.0%. SSi Mantra installations rose to 103 (+119.1%) and cumulative surgeries reached 7,885. The company completed a private placement raising ~$18.6M and had $3.2M cash as of December 31, 2025.
Fourth-quarter revenue was $14.5M (+79.1%) with 40 installations. Full-year net loss improved to $12.1M from $19.2M in 2024. Management expects FDA 510(k) review by mid-2026 and continued global expansion.
SS Innovations (NASDAQ: SSII) completed a private placement on March 6, 2026, raising approximately $18.6 million in gross proceeds through the sale of 5,774,839 common shares.
The offering included insider purchases by the CEO, vice-chairman and a director, a $2.5 million investor that triggered a 7% cash commission and five-year warrants, and participation led by Manipal Global Health Services. Proceeds will fund working capital and global expansion, including planned U.S. FDA 510(k) review and EU CE marking efforts for the SSi Mantra surgical robotic system.
SS Innovations (Nasdaq: SSII) reported preliminary unaudited results for Q4 and full-year 2025 showing significant unit and revenue growth. Q4 2025 revenue is estimated at $15.0 million, up 85% from $8.1 million a year earlier, with 37 SSi Mantra installations in the quarter, up 68% year-over-year. Full-year 2025 revenue is estimated at $43.0 million, up 108% from $20.6 million in 2024, and 103 SSi Mantra installations for the year, up 119%.
The cumulative installed base reached 168 systems at year-end 2025. Management said FDA 510(k) review and EU CE marking are anticipated in the first half of 2026. Results are preliminary, unaudited and subject to final quarter-end procedures and change.
SS Innovations (Nasdaq: SSII) appointed Milan Rao as Global Chief Operating Officer and Chief Financial Officer effective January 8, 2026. The Global COO role is newly created; Mr. Rao will succeed Naveen Kumar Amar as CFO following Mr. Amar’s resignation for personal reasons and will be based in the United States during a planned transition period. Mr. Rao brings more than three decades of leadership across healthcare, technology and financial services, with prior roles at Markets and Markets, Wipro, GE Healthcare, Morgan Stanley and Citibank.
The company said Mr. Rao will support growth strategy, operational readiness and scaling of the SSi Mantra surgical robotic platform.
SS Innovations (Nasdaq: SSII) announced completion of five new 5-millimeter surgical instruments for clinical use with its SSi Mantra robotic system, targeting pediatric, cardiac, and head-and-neck procedures. The instruments are a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.
As of Dec 31, 2025, the SSi Mantra installed base totaled 168 systems across 153 hospitals, with more than 7,800 procedures performed, including over 120 telesurgeries and more than 400 cardiac procedures. The company says the smaller instruments aim to expand robotic access for children and other patients with small anatomical structures.
SS Innovations (Nasdaq: SSII) submitted a 510(k) premarket notification to the FDA on Dec 5, 2025 for the SSi Mantra surgical robotic system covering general, urological, colorectal, gynecological and cardiac surgeries.
The company said it chose the 510(k) pathway following FDA pre-submission talks to seek faster, lower-cost review; the FDA aims for 90-day reviews but noted potential delays from the 15-day acceptance review or requests for more information. SS Innovations also expects possible EU CE marking in H1 2026.
As of Nov 30, 2025, the SSi Mantra installed base totaled 138 systems across eight countries, with 137 hospitals and over 7,300 procedures performed, including 88 telesurgeries and 390 cardiac procedures.